Shots:
- AstraZeneca has reported P-III (Bax24) trial data assessing baxdrostat (2mg; QD) + SoC vs PBO + SoC in 218 pts with treatment-resistant hypertension for 12wks.
- Trial achieved its 1EP, showing reduced 24hr. ambulatory systolic blood pressure at 12wks., with consistent efficacy across the day, incl. early morning; data to be presented at AHA’25 & shared with global health authorities
- Baxdrostat is also being evaluated as a monotx. for hypertension & primary aldosteronism as well as in combination with dapagliflozin for chronic kidney disease & prevention of heart failure in high-risk pts
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca and Daiichi Sankyo Report P-III (TROPION-Breast02) Trial Results of Datroway for Triple-Negative Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
